MEK (Mitogen-activated protein kinase kinase, MAPKK) is a kinase enzyme which phosphorylates mitogen-activated protein kinases (MAPKs).The downstream transcription factors that control responses like stress signaling, pathogen response, and hormone signaling are phosphorylated as a result of the activated MAPK.
The final protein in the cascade, a MAPK (ERK, p38, or JNK), is activated by the MAPKKK by phosphorylating a serine or threonine residue on a MAPKK. Mitogen-activated protein kinase kinase 3 (MKK3), MKK6, and occasionally MKK4 are primarily responsible for activating the p38 MAPK. Two upstream MAP2Ks, MKK4 and MKK7, control the JNK. Raf and Ras are activated by the highly homologous kinases MEK1 and MEK2, which then activate ERK mitogen-activated protein kinases.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V1991 | Myricetin (Cannabiscetin) | 529-44-2 | Myricetin (Cannabiscetin), a naturally occuring flavonoid with antioxidant and anti tumor properties, is a novel inhibitor of MEK1 activity and transformation of JB6 P+ mouse epidermal cells. |
|
V0454 | Binimetinib ( Mektovi; ARRY438162; ARRY162; MEK162) | 606143-89-9 | Binimetinib (trade name:Mektovi; formerly ARRY-438162; ARRY-162; MEK-162) is a highly selective and orally bioavailable MEK1/2(mitogen-activated protein kinase kinase) inhibitor with potential antineoplastic activity. |
|
V3734 | Trans-Zeatin | 1637-39-4 | Trans-Zeatin is a plant hormone /cytokinin that plays an important role in cell growth, differentiation, and division, it promotes growth of lateral buds, stimulates seed germination and seedling growth, and induces cell division. |
|
V0461 | Refametinib (RDEA119, BAY86-9766) | 923032-37-5 | Refametinib (formerly RDEA-119, BAY 86-9766) is an orally bioavailable, highly selective and non-ATP-competitive (allosteric) inhibitor of MEK1/2 with potential antitumor activity. |
|
V37565 | Selumetinib sulfate (AZD6244 sulfate) | 943332-08-9 | Selumetinib sulfate (also known as AZD6244 sulfate; ARRY-142886 sulfate) is a novel, potent, highly selective, orally bioavailable, andnon-ATP-competitivesmall molecule MEK1 inhibitor with IC50 of 14 nM in cell-free assays and with anticancer activity, it also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. |
|
V0445 | Mirdametinib (PD0325901) | 391210-10-9 | Mirdametinib (PD-0325901) is a novel, potent,selective, orally bioavailable and non ATP-competitive inhibitor of the mitogen-activated protein kinaseMEK with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. |
|
V0453 | Cobimetinib (GDC-0973, RG-7420, XL-518) | 934660-93-2 | Cobimetinib (formerly GDC0973, RG7420, XL518; trade name Cotellic) is an orally bioavailable and selective small-molecule inhibitor of MEK1 with potential anticancer activity. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
